Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BioNTech SE
  6. News
  7. Summary
    BNTX   US09075V1026

BIONTECH SE

(BNTX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

BioNTech : will take two weeks to assess vaccine against latest Covid variant - Form 6-K

11/26/2021 | 05:10pm EST
BioNTech will take two weeks to assess vaccine against latest Covid variant
Hannah Kuchler

BioNTech will know in two weeks whether the vaccine it developed with Pfizer will work against the new B.1.1.529 variant of Covid that has emerged in southern Africa.

The German company says it is testing the vaccine against the strain in the lab. It said the variant "differs significantly from previously observed variants" because of additional mutations on the spike protein, which vaccines target.

"Pfizer and BioNTech have taken actions months ago to be able to adapt the mRNA vaccine within six weeks and ship initial batches within 100 days in the event of an escape variant," the company said.

"To that end, the companies have begun clinical trials with variant-specific vaccines (alpha and delta) to collect safety and tolerability data that can be provided to regulators."

Shares in BioNTech climbed 7.2 per cent to $326.56 in pre-market trading, while partner Pfizer added 5.6 per cent to $53.75.

Disclaimer

BioNTech SE published this content on 26 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 26 November 2021 22:09:03 UTC.


© Publicnow 2021
All news about BIONTECH SE
04:52aBIONTECH : Goldman Sachs sticks Neutral
MD
01/18Fourth Pfizer-BioNTech COVID-19 Shot Fails to Prevent Omicron Infection in Israeli Stud..
MT
01/18Morgan Stanley Adjusts BioNTech's Price Target to $284 from $294, Keeps Equalweight Rat..
MT
01/18European ADRs Move Lower in Tuesday Trading
MT
01/18European Medicines Agency Says mRNA COVID-19 Vaccines Safe In Pregnancy
MT
01/14Omicron leaves Germany on brink of recession as growth dips
AQ
01/14German economy short of pre-pandemic level despite 2.7% growth in 2021
RE
01/13European ADRs Move Higher in Thursday Trading
MT
01/13Acuitas Therapeutics Names Miranda Lam as
AQ
01/13Positive Top-Line Results of Pfizer's Phase 3 Study Exploring Coadministration of PREVN..
AQ
More news
Analyst Recommendations on BIONTECH SE
More recommendations
Financials
Sales 2021 17 454 M 19 790 M 19 790 M
Net income 2021 9 220 M 10 454 M 10 454 M
Net cash 2021 8 918 M 10 111 M 10 111 M
P/E ratio 2021 4,07x
Yield 2021 -
Capitalization 36 079 M 40 873 M 40 908 M
EV / Sales 2021 1,56x
EV / Sales 2022 1,06x
Nbr of Employees 2 800
Free-Float -
Chart BIONTECH SE
Duration : Period :
BioNTech SE Technical Analysis Chart | BNTX | US09075V1026 | MarketScreener
Technical analysis trends BIONTECH SE
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 16
Last Close Price 149,38 €
Average target price 263,77 €
Spread / Average Target 76,6%
EPS Revisions
Managers and Directors
Ugur Sahin Chief Executive Officer
Jens Holstein Chief Financial Officer
Helmut Jeggle Chairman-Supervisory Board
Özlem Türeci Chief Medical Officer
Sierk Pötting Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
BIONTECH SE-34.36%40 873
GILEAD SCIENCES, INC.-3.00%88 346
REGENERON PHARMACEUTICALS-3.21%63 906
VERTEX PHARMACEUTICALS5.22%58 750
WUXI APPTEC CO., LTD.-0.66%54 178
BEIGENE, LTD.-11.55%24 621